Breaking News, Collaborations & Alliances

Astellas Pharma, Vir Biotechnology Partner to Advance VIR-5500

VIR-5500 is an investigational PRO-XTEN dual-masked CD3 T-cell engager (TCE) targeting PSMA for the treatment of prostate cancer.

Author Image

By: Charlie Sternberg

Associate Editor

Astellas Pharma Inc. and Vir Biotechnology Inc. have entered into a global strategic collaboration to advance VIR-5500, an investigational PRO-XTEN dual-masked CD3 T-cell engager (TCE) targeting PSMA for the treatment of prostate cancer. The collaboration aims to accelerate the development of VIR-5500 and further strengthen Astellas’ oncology pipeline and prostate cancer leadership. Treating Prostate Cancer Despite recent advances in treatment, prostate cancer, especially metastatic ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters